Studies of novel centrally acting drugs in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be obtained from biomarkers of clinical endpoints. This paper provides a systematic overview of CNS-tests used with SSRIs in healthy subjects. A useful biomarker should meet the following requirements: a consistent response across studies and drugs; a clear response of the biomarker to a therapeutic dose; a dose-response relationship; a plausible relationship between biomarker, pharmacology and pathogenesis.
Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.
CHDR
Dumont GJ, de Visser SJ, Cohen AF, van Gerven JM,
